Stock Track | Viking Therapeutics Soars 9.91% in Post-Market on Positive Pipeline Updates Despite Earnings Miss

Stock Track

Feb 12

Viking Therapeutics' stock surged 9.91% in post-market trading on Wednesday, as investors focused on encouraging updates across the company's clinical development pipeline, overshadowing a wider-than-expected fourth-quarter loss.

The biopharmaceutical company reported a Q4 net loss of $157.7 million, or $1.38 per share, which missed analyst estimates. However, the market reaction was driven by several key announcements regarding its obesity drug portfolio. Viking Therapeutics plans to advance its oral VK2735 formulation into Phase 3 trials for obesity in the third quarter of 2026. The company highlighted that the availability of both an oral and an injectable formulation is a key differentiator for VK2735, as no other dual or triple agonist is currently available in both forms.

Additional positive updates included strong enrollment progress in the Phase 3 VANQUISH trials for the subcutaneous formulation of VK2735, the completion of enrollment for a VK2735 maintenance dosing study with data expected in 3Q26, and plans to file an Investigational New Drug (IND) application for a novel amylin agonist this quarter. The company also reported a strong cash position of $706 million at year-end, providing ample resources to advance its clinical programs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1135508426"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135508426\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135508426?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 09:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135508426","market":"us","top_or_hot":-1,"title":"Stock Track | Viking Therapeutics Soars 9.91% in Post-Market on Positive Pipeline Updates Despite Earnings Miss","media":"Stock Track","content":"<p>Viking Therapeutics' stock surged 9.91% in post-market trading on Wednesday, as investors focused on encouraging updates across the company's clinical development pipeline, overshadowing a wider-than-expected fourth-quarter loss.</p><p>The biopharmaceutical company reported a Q4 net loss of $157.7 million, or $1.38 per share, which missed analyst estimates. However, the market reaction was driven by several key announcements regarding its obesity drug portfolio. Viking Therapeutics plans to advance its oral VK2735 formulation into Phase 3 trials for obesity in the third quarter of 2026. The company highlighted that the availability of both an oral and an injectable formulation is a key differentiator for VK2735, as no other dual or triple agonist is currently available in both forms.</p><p>Additional positive updates included strong enrollment progress in the Phase 3 VANQUISH trials for the subcutaneous formulation of VK2735, the completion of enrollment for a VK2735 maintenance dosing study with data expected in 3Q26, and plans to file an Investigational New Drug (IND) application for a novel amylin agonist this quarter. The company also reported a strong cash position of $706 million at year-end, providing ample resources to advance its clinical programs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Viking Therapeutics Soars 9.91% in Post-Market on Positive Pipeline Updates Despite Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Viking Therapeutics Soars 9.91% in Post-Market on Positive Pipeline Updates Despite Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-12 09:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viking Therapeutics' stock surged 9.91% in post-market trading on Wednesday, as investors focused on encouraging updates across the company's clinical development pipeline, overshadowing a wider-than-expected fourth-quarter loss.</p><p>The biopharmaceutical company reported a Q4 net loss of $157.7 million, or $1.38 per share, which missed analyst estimates. However, the market reaction was driven by several key announcements regarding its obesity drug portfolio. Viking Therapeutics plans to advance its oral VK2735 formulation into Phase 3 trials for obesity in the third quarter of 2026. The company highlighted that the availability of both an oral and an injectable formulation is a key differentiator for VK2735, as no other dual or triple agonist is currently available in both forms.</p><p>Additional positive updates included strong enrollment progress in the Phase 3 VANQUISH trials for the subcutaneous formulation of VK2735, the completion of enrollment for a VK2735 maintenance dosing study with data expected in 3Q26, and plans to file an Investigational New Drug (IND) application for a novel amylin agonist this quarter. The company also reported a strong cash position of $706 million at year-end, providing ample resources to advance its clinical programs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VKTX","symbol_name":"Viking Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1135508426","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135508426","pubTimestamp":1770858369,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Viking Therapeutics' stock surged 9.91% in post-market trading on Wednesday, as investors focused on encouraging updates across the company's clinical development pipeline, overshadowing a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VKTX":"Viking Therapeutics, Inc."},"translate_title":"股票追踪|Viking Therapeutics尽管盈利未达预期，但仍因积极的管道更新而盘后飙升9.91%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1},"content_text":"Viking Therapeutics' stock surged 9.91% in post-market trading on Wednesday, as investors focused on encouraging updates across the company's clinical development pipeline, overshadowing a wider-than-expected fourth-quarter loss.The biopharmaceutical company reported a Q4 net loss of $157.7 million, or $1.38 per share, which missed analyst estimates. However, the market reaction was driven by several key announcements regarding its obesity drug portfolio. Viking Therapeutics plans to advance its oral VK2735 formulation into Phase 3 trials for obesity in the third quarter of 2026. The company highlighted that the availability of both an oral and an injectable formulation is a key differentiator for VK2735, as no other dual or triple agonist is currently available in both forms.Additional positive updates included strong enrollment progress in the Phase 3 VANQUISH trials for the subcutaneous formulation of VK2735, the completion of enrollment for a VK2735 maintenance dosing study with data expected in 3Q26, and plans to file an Investigational New Drug (IND) application for a novel amylin agonist this quarter. The company also reported a strong cash position of $706 million at year-end, providing ample resources to advance its clinical programs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}